To the full analysis
Ascentage Pharma Group International stock: growth
AAPGAscentage Pharma Group International reported $83.75M in revenue for fiscal 2025, down 43.1% on the prior year, up 114% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
61%
per year from 2016 to 2025, per share 30%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 114.0% | 61.0% |
| Revenue per share | 46.7% | 30.0% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $1.15M | −$16.17M | −$7.39M |
| 2017 | $948.97K | −$17.77M | −$19.27M |
| 2018 | $1.02M | −$51.78M | −$43.06M |
| 2019 | $2.18M | −$222.05M | −$81.24M |
| 2020 | $1.87M | −$101.62M | −$129.18M |
| 2021 | $4.19M | −$117.34M | −$156.16M |
| 2022 | $31.45M | −$132.41M | −$133.6M |
| 2023 | $33.29M | −$138.81M | −$117.41M |
| 2024 | $147.06M | −$60.8M | −$20.34M |
| 2025 | $83.75M | −$181.29M | −$180.21M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 23 Jan 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.